NASDAQ$GERN
Geron Corp · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Geron reported a net loss for Q3 2021, highlighted the potential of Imetelstat, and summarized key takeaways from its Investor Event.
Geron Corporation reported its Q3 2021 financial results, including a net loss of $26.7 million, and summarized key highlights from its Investor Event, where the company emphasized the disease-modifying activity of Imetelstat and its potential in treating hematologic malignancies.
- Imetelstat shows strong evidence of disease-modifying activity.
- Phase 3 development programs in lower risk MDS and refractory MF are underway.
- New programs are expanding potential indications and combination opportunities for Imetelstat.
- Company estimates potential peak revenue of more than $3 billion for imetelstat from the United States and the five largest countries in the European Union.
Headline financials
Revenue & EPS history
Geron · Revenue · Quarterly
$109K
Revenue by segment
Geron · $164K total across 1 segment · Q3 2023
- Royalties$164K—100.0%
Forward guidance
Geron anticipates several key milestones and developments in the near future, including the availability of top-line results from the IMerge Phase 3 trial, the opening of the first clinical site for IMproveMF, the initiation of IMpress and TELOMERE trials, and the availability of preliminary results from the preclinical program in lymphoid malignancies.
Tailwinds
- Top-line results from IMerge Phase 3 are expected at the beginning of January 2023.
- Interim analysis for IMpactMF is expected in 2024, and the final analysis in 2025.
- The first clinical site for IMproveMF is expected to open in the first half of 2022.
- IMpress is expected to begin in the first half of 2022.
- TELOMERE is expected to begin in the first half of 2022.
Headwinds
- The COVID-19 pandemic could materially and adversely impact Geron’s business and business prospects.
- Geron faces potential delays and other adverse impacts caused by the COVID-19 pandemic.
- Regulatory authorities may not permit the further development of imetelstat on a timely basis, or at all, without any clinical holds.
- Future efficacy or safety results may cause the benefit-risk profile of imetelstat to become unacceptable.
- There may be failures or delays in manufacturing or supplying sufficient quantities of imetelstat or other clinical trial materials in a timely manner.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+0.6%
Avg return
Earnings day
-1.3%
Avg return
5 days after
+4.2%
Avg return
30 days after
42%
27 / 64 earnings
Positive
+35.3%
Q4 2013
Best reaction
-32.1%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.2% | -15.8% | -29.1% | |
| Q4 2025 | -11.3% | -20.5% | -28.2% | |
| Q3 2025 | -4.5% | +0.9% | +13.9% | |
| Q1 2025 | -0.8% | -3.0% | +21.2% | |
| Q4 2024 | -32.1% | -27.8% | -30.4% | |
| Q3 2024 | -0.5% | -7.0% | -8.0% | |
| Q2 2024 | +3.1% | +0.2% | -6.8% | |
| Q1 2024 | -3.7% | -5.1% | -13.0% | |
| Q4 2023 | -3.4% | +0.5% | +59.4% | |
| Q3 2023 | +2.6% | -1.0% | +3.1% | |
| Q2 2023 | -7.5% | -7.5% | -22.5% | |
| Q1 2023 | +9.9% | +6.0% | +27.7% | |
| Q4 2022 | -3.4% | -10.7% | -24.8% | |
| Q3 2022 | -2.3% | +0.9% | +7.0% | |
| Q2 2022 | +8.3% | +2.3% | +22.1% | |
| Q1 2022 | +13.8% | +11.5% | +8.5% | |
| Q4 2021 | +0.9% | -3.7% | +46.3% | |
| Q3 2021 | -9.3% | -8.7% | -21.5% | |
| Q2 2021 | +4.9% | +4.1% | +11.5% | |
| Q1 2021 | +4.5% | +7.5% | +12.8% | |
| Q4 2020 | -6.0% | -3.3% | -19.1% | |
| Q3 2020 | -4.8% | -0.5% | -2.7% | |
| Q2 2020 | -2.3% | -7.0% | +6.4% | |
| Q1 2020 | -1.8% | +0.0% | +17.7% | |
| Q4 2019 | -6.8% | -7.8% | +7.8% | |
| Q3 2019 | +0.7% | +0.0% | +2.0% | |
| Q2 2019 | -3.3% | -0.8% | +16.7% | |
| Q1 2019 | -0.6% | -3.3% | -19.9% | |
| Q4 2018 | +0.7% | +7.7% | +27.3% | |
| Q3 2018 | +9.2% | +7.8% | +5.2% | |
| Q2 2018 | +4.5% | +4.8% | +63.6% | |
| Q1 2018 | -9.9% | -10.9% | -2.1% | |
| Q4 2017 | +24.7% | +43.4% | +10.6% | |
| Q3 2017 | -8.9% | -8.4% | -14.2% | |
| Q2 2017 | -7.1% | -8.4% | -5.8% | |
| Q1 2017 | +0.8% | +11.7% | +4.7% | |
| Q4 2016 | +2.3% | -0.9% | +5.6% | |
| Q3 2016 | +2.7% | +2.2% | +8.6% | |
| Q2 2016 | -0.4% | +0.0% | +1.1% | |
| Q1 2016 | -2.2% | — | — | |
| Q4 2015 | -4.2% | — | — | |
| Q3 2015 | +3.4% | — | — | |
| Q2 2015 | -7.8% | — | — | |
| Q1 2015 | +3.1% | — | — | |
| Q4 2014 | -7.0% | — | — | |
| Q3 2014 | +20.2% | — | — | |
| Q2 2014 | -5.3% | — | — | |
| Q1 2014 | -6.4% | — | — | |
| Q4 2013 | +35.3% | — | — | |
| Q3 2013 | +28.2% | — | — | |
| Q2 2013 | +14.6% | — | — | |
| Q1 2013 | -1.8% | — | — | |
| Q4 2012 | -5.1% | — | — | |
| Q3 2012 | -1.5% | — | — | |
| Q2 2012 | +3.8% | — | — | |
| Q1 2012 | -0.7% | — | — | |
| Q4 2011 | -0.6% | — | — | |
| Q3 2011 | +4.2% | — | — | |
| Q2 2011 | -15.6% | — | — | |
| Q1 2011 | +0.0% | — | — | |
| Q4 2010 | +1.7% | — | — | |
| Q3 2010 | -4.5% | — | — | |
| Q2 2010 | +26.4% | — | — | |
| Q1 2010 | +3.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro